![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Octapharma to Test Immune-Globulin Treatment for COVID-19 Patients
Octapharma to Test Immune-Globulin Treatment for COVID-19 Patients
Octapharma USA is launching a phase 3 trial of its Octagam 10 percent immune-globulin solution as a possible treatment for COVID-19 patients with severe disease progression.
The trial will assess whether the therapy can slow or stop respiratory deterioration. Patients will be randomized to receive either the intravenous immune globulin or a placebo.
The trial at 10 U.S. sites will enroll approximately 54 adults with severe COVID-19 and oxygen saturation of less than 93 percent.
Upcoming Events
-
18Jul
-
21Oct